Welcome to the ISCB Community News Blog

This blog collects news, announcements or other information which could be of interest to our ISCB members. We are a group ISCB members who volunteer to populate this blog on a regular basis. In case you want to become an "ISCB-News Reporter" yourself, let us know: contact ISCB
Don't repost copyrighted content! The guidelines are:
- Include a link to the source page
- Include a short summary about the article. You can quote up to ONE paragraph from the original story, but not more
- Don't repost an entire articles originating from another source
- Never post content without attribution — always include the source

To post a news, please use this form.

Wednesday, April 29, 2015

FASEB PRESIDENT TESTIFIES BEFORE CONGRESS

Bethesda, MD – The President of the Federation of American Societies for Experimental Biology (FASEB), Joseph R. Haywood, PhD, testified before the House Appropriations Subcommittee on Labor, Health and Human Services on April 29. Dr. Haywood advocated for sustained, predictable increases in funding for the National Institutes of Health (NIH).

Dr. Haywood asked the subcommittee to appropriate $32 billion for NIH in fiscal year 2016. He explained that a five year commitment to five percent annual increases would help restore the buying power of the NIH budget, which has declined by more than 22 percent since 2003.

"Every one of us is the spouse, parent, child, dear friend, or acquaintance of someone who is relying on our nation's scientists and physicians to develop tomorrow's treatments," Dr. Haywood told the subcommittee. "[NIH] investment is critical to expedite progress toward the cures that are so desperately needed for all of our loved ones, and for developing innovative technologies and new global industries to sustain the nation's continued economic recovery," he said.

FASEB is composed of 27 societies with more than 120,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
URL: http://www.faseb.org

Contact Person: Debra Speert (dspeert@faseb.org)

Call for Papers: CIBB 2015 special session on 'New knowledge from old data: power of data analysis and integration methods'

September 10-12, 2015
Naples, Italy
http://bioinfo.na.iac.cnr.it/cibb2015/

AIMS AND SCOPE:
Mammalian systems constitute over 200 cell types, each specialized to perform a distinct function, and yet all cell types share the same DNA sequence. Epigenetic marks on DNA and histone tails together with transcription factors are responsible for the interpretation of the DNA sequence in each cellular context to produce a cell type specific transcription signature, and disruptions to these processes lead to disease. Advances in sequencing techniques have accelerated the characterization of epigenetic and transcriptional landscapes across many normal and malignant cell types. The challenge now is to integrate these data to understand transcriptional control at a systems level.

This session will focus on data analysis and data integration methods developed using data from, but not limited to, large consortia projects such as ENCODE, Roadmap Epigenomics or FANTOM to get new biological insights.

SUBMISSIONS:
Conference papers must be prepared following the guidelines illustrated on the CIBB website, which include the requirement of being between 4 and 6 pages in length and having five sections:
1. Scientific background
2. Material and methods
3. Results
4. Conclusion
5. References (no more than 10)

These papers should be submitted in PDF format on the Easy Chair conference system (it is necessary to select this special session in the submission system).
A second submission after the conference, in an extended version, is required to be considered for publication in the Springer\\\'s Lecture Notes in Bioinformatics (LNBI) series ([link]). Moreover, as it has been the case in previous CIBB conferences, we are planning to publish the best papers of CIBB 2015 in an extended form in a special issue of an international scientific journal, including special session papers.

IMPORTANT DATES:
Paper submission deadline: May 30, 2015
Abstract submission deadline: May 30, 2015
Notification of Acceptance: June 19, 2014 Final papers due: July 20, 2015 (*)
Conference: September 10-12, 2015
(*) for the inclusion in the CIBB15 conference proceeding

URL: http://bioinfo.na.iac.cnr.it/cibb2015/

Contact Person: Anagha Joshi (anagha.joshi@roslin.ed.ac.uk)

Tuesday, April 14, 2015

New Master in Bioinformatics at Ghent University

Recent technological advances allow for the generation of huge amounts of molecular data at an ever increasing pace and have dramatically changed our view on life science research. It goes without saying that this data avalanche, together with the need for multi-angle approaches to analyze these data, has created an urgent need for highly trained scientists with an interdisciplinary mindset. The new interfaculty Master of Science in Bioinformatics at Ghent University will start in the academic year 2015-2016 and aims to provide students with the necessary knowledge, skills and attitude to work in such interdisciplinary context.

This Master of Science in Bioinformatics provides a curriculum of 120 ECTS, taught in English. Bioinformatics is inherently multidisciplinary, and requires not only learning skills and knowledge from domains different than those of the bachelor\\\'s degree, but also acquiring a more in-depth knowledge and training in the domain that corresponds to the students' specific background and primary interest. The master is structured to provide both this broadening and deepening.

In a common track (33 ECTS) the master offers courses covering the different application domains of bioinformatics. This track, followed by all students irrespective of their background, primarily aims at educating the interdisciplinary competences that are of key importance to bioinformatics.

Depending on the specific background of the student, this common track is complemented with one of the following specialization tracks (each of which is 87 ECTS):

- Bioscience Engineering (title of 'Bioscience engineer')
- Systems Biology
- Engineering (title of 'Engineer')
URL: http://www.nucleotides2networks.be/master

Contact Person: Dr. Katrijn Vannerum (Katrijn.Vannerum@UGent.be)

Registration Open - Functional Genomics and Systems Biology: From Model Organisms

This long-running Wellcome Trust conference will bring together leading scientists from the fields of genomics, bioinformatics, proteomics and cellular networks to discuss the latest developments and challenges in systems biology.

Advances in DNA sequencing and other high throughput technologies over the past decade have resulted in a wealth of data describing the functions and interactions of various components within the cell. High-resolution maps of genome-wide transcription factors are shedding light on the mechanisms that regulate gene expression. Large-scale interaction networks are improving our understanding of biological systems. To improve our understanding of complex biological systems relevant to health and disease, these data, generated from disparate sources, need to be integrated in a biologically meaningful way.

This conference is an ideal forum to discuss the integration, interpretation and analysis of complex biological data from experimental and computational sources. We welcome the submission of abstracts from all areas relevant to the main themes of the meeting. Several oral presentations will be chosen from the abstracts submitted.


Topics will include
High throughput technologies: applications and analysis
Functional genomics of disease
Model organisms
Single cell analysis
Genome and epigenome regulation
Human genetic variation
Complex networks
Modelling biological networks and pathways


Scientific programme committee
Alvis Brazma EMBL-EBI, UK
Tom Freeman University of Edinburgh, UK
Anne-Claude Gavin EMBL, Germany
Tuuli Lappalainen New York Genome Center, USA
Nicholas Luscombe University College London, UK

Confirmed speakers
Ruedi Aebersold ETH Zurich, Switzerland
Emmanuelle Charpentier Helmholtz Centre for Infection Research, Germany
Peter Fraser Babraham Institute, UK
Marc Friedlander SciLifeLab/Stockholm University, Sweden
Eileen Furlong EMBL, Germany
Roderic Guigo Centre for Genomic Regulation, Spain
Tim Hughes University of Toronto, Canada
Jan Korbel EMBL, Germany
Laura Landweber Princeton University, USA
Ben Lehner Centre for Genomic Regulation, Spain
Leopold Parts Wellcome Trust Sanger Institute, UK
James Sharpe Centre for Genomic Regulation, Spain
Sarah Teichmann EMBL-EBI, UK
Marian Walhout University of Massachusetts Medical School, USA
Michael Yaffe Massachusetts Institute of Technology, USA
Judith Zaugg EMBL, Germany

Dates for your diary:
Abstract & Bursary deadline: 16 September

Registration deadline: 30 September


URL: https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=517

Contact Person: Treasa Creavin (treasa.creavin@hinxton.wellcome.ac.uk)

FASEB Releases New Interactive Map of Federal Science Funding By District

FASEB Releases New Interactive Map of Federal Science Funding By District
Online resource is freely available to the public

Bethesda, MD – The Federation of American Societies for Experimental Biology (FASEB) has released new interactive factsheets summarizing federal science funding in states and U.S. congressional districts. This is the only resource to feature up-to-date information about federal science funding at the district level and make it accessible to the general public.

"This innovative resource illustrates how federal investment in scientific research affects communities in every state," stated Joseph R. Haywood, PhD, FASEB President. "This is an easy way to help our representatives appreciate the impact of federal agency funding on science back home. More importantly, we urge scientists and the public to use this resource to discuss the importance of science funding with their elected officials."

After selecting a state from an online interactive U.S. map, users can drill down to access federal science funding in a single congressional district. Factsheets for each district detail local federal investment by the National Institutes of Health (NIH), National Science Foundation, United States Department of Agriculture, and Department of Energy. In addition to district funding data, users can also access factsheets detailing the impact of NIH investment in each state from the same map.

The district funding information is being shared with more than 100 congressional offices during FASEB's annual Capitol Hill Day today. Fifty representatives of FASEB member societies from 27 states are meeting with House and Senate offices to share FASEB's fiscal year 2016 funding recommendations as well as personal stories of how stable, sustained federal funding for research is essential to improve health and generate new knowledge.

FASEB is composed of 27 societies with more than 120,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
URL: http://www.faseb.org

Contact Person: Lawrence Green (lgreen@faseb.org)

Tuesday, April 7, 2015

Opportunity for early- career bioscientists: Clarkson Early Career Colloquium in Bioscience Crossing Disciplines

Dear Fellow Chairs & Program Heads of Bioscience Departments,

As Chair of Biology at Clarkson University, I am writing to ask for your help at getting out the word and encouraging appropriate applicants for the inaugural Clarkson Early Career Colloquium in Bioscience Crossing Disciplines. This mini-conference is intended for early- career bioscientists, with particular outreach to women and underrepresented minorities seeking academic appointments at small research universities that also have a strong commitment to undergraduate and graduate education. Participants will have an opportunity to network and receive mentoring on how to land a job and what it is like to have a position at an academic institution with high research and teaching expectations such as Clarkson, or at a small research institute such as the Trudeau Institute. It provides an opportunity for Clarkson University and the Trudeau Institute, which intend to be hiring for more positions in the coming years, to meet and make contacts with promising scientists who could enhance and diversify our bioscience faculty. For this first colloquium, we are interested in broad areas of biosciences, including but not limited to bioengineering (including immunoengineering), ecological/evolutionary epidemiology, bioinformatics; behavioral endocrinology, biotechnology, cell biology, and synthetic biology.

I have attached a flyer and detailed announcement of the program. An advertisement will also soon appear in the Chronical of Higher Education.

Please feel free to forward this message to colleagues at your institution or elsewhere who mentor or may know appropriate candidates for this colloquium.


Tom Langen

Chair, Dept. of Biology
Professor, Depts. of Biology, Psychology
Clarkson University
Editorial Board, Environmental Management
mail: (office) Box 5805, Clarkson University, Potsdam NY 13699-5805
mail: (home) 7 Pleasant St., Canton NY 13617
phone:315 268 7933 (office), 315 261 0182 (cell)
URL: http://clarkson.edu/colloquium/

Contact Person: Dr. Tom Langen (tlangen@clarkson.edu)

Monday, April 6, 2015

Quantitative Biology: From Molecules to Man

Quantitative Biology: From Molecules to Man will bring together professionals in science, medicine, and engineering to articulate a vision for the future of improving patient health outcomes. Convergence science provides for a data-driven understanding of intricate biological processes across spatial and temporal scales. Achieving breakthroughs in healthcare requires a specific progression of steps from molecular-level experiments to manipulations and observations in model systems to human-scale investigations, all followed by major epidemiological studies. This one-day meeting will provide a forum for individuals involved in every stage of the process to engage in thought-provoking conversations and to generate actionable ideas for new approaches to finding solutions to some of humanity's most intractable health challenges. For more information please visit the website: www.nyas.org/QuantitativeBiology2015.
Poster Abstract Deadline: May 11, 2015

URL: http://www.nyas.org/QuantitativeBiology2015

Contact Person: Natasha Neysmith (nneysmith@nyas.org)

Thursday, April 2, 2015

IMPACT-F optimizes lead candidates in drug discovery

Pharmaceutical companies use the expert system to forecast drug-uptake in humans.

The artificial intelligence technology, developed by PharmaInformatic, Germany, evaluates if a potential drug will be efficiently taken up in humans. IMPACT-F prioritizes drug-candidates based on predicted drug-uptake ("oral bioavailability"). This ranking allows the most efficient drug-candidates to be chosen for further development.

The technology has been used in therapeutic areas such as cancer, diabetes, inflammation, antivirals and autoimmune diseases. It has been applied to optimize lead candidates and to evaluate oral bioavailability and effective dose prior to human clinical trials. The first drug candidates evaluated with IMPACT-F have now progressed into clinical trials in humans.

Crucially, IMPACT-F improves drug discovery and development at a very early stage, since only the drug structure is needed to reliably forecast oral bioavailability. This enables pharmaceutical companies to focus resources on prospective drug development projects.

Oral bioavailability is one of the most important properties in lead optimisation. A drug must have sufficient oral bioavailability in humans otherwise clinical trials are not effective and drug development is then stopped. Low drug-uptake can result in high inter-individual variability and increases the risk of side-effects and toxicity.


Contact:
Dr. Wolfgang Boomgaarden, phone: +49-4921-993360
PharmaInformatic Boomgaarden, Friesenstr. 36, 26721 Emden, Germany, http://www.pharmainformatic.com
Twitter: https://twitter.com/PharmaInformati

Further detailed information:
http://www.pharmainformatic.com/html/lead_optimization.html#PM

Pharmaceutical companies using IMPACT-F (recent collaborations):
http://www.pharmainformatic.com/html/partnerships.html

URL: http://www.pharmainformatic.com/html/lead_optimization.html

Contact Person: Dr. Wolfgang Boomgaarden (presse@pharmainformatic.com)